Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 29Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Head & Neck 2Gastrointestinal 2CNS 2Breast 2Tumor-Agnostic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Solid Tumor 1

Interventions

pembrolizumab 14Injections 13Pemetrexed 9Specimen Handling 8Carboplatin 8tislelizumab 7Interviews as Topic 7Cisplatin 7fludarabine 5atezolizumab 5Educational Status 5Cyclophosphamide 5Standard of Care 4Practice Guidelines as Topic 4Methods 4Fluorouracil 4Early Intervention, Educational 4Capecitabine 4Biopsy 4Bevacizumab 4Trastuzumab 3Platinum 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Magnetic Resonance Spectroscopy 3Docetaxel 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
osimertinib × Other solid neoplasm × 30 days × Clear all
NCT07612137 2026-05-28

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Not yet recruiting
282 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡